Clinical safety of drug-eluting stents in the Korea acute myocardial infarction registry

Rok Lee Sang, Ho Jeong Myung, Keun Ahn Young, Chull Chae Shung, Ho Hur Seung, Jo Kim Young, Whan Seong In, Keon Chae Jei, Jong Hong Taek, Young Rhew Jae, Chan Cho Myeong, Ho Bae Jang, Woon Rha Seung, Jin Kim Chong, Soo Jang Yang, Jung Park Seung, Hyun Kim Jong, Hoon Choi Dong, Il Kim Doo, Ho Chae InHan Yoon Jung, Kwon Koo Bon, Ok Kim Byung, Yong Lee Myoung, Sik Kim Kee, Yong Hwang Jin, Kyu Oh Seok, Hee Lee Nae, Tae Jeong Kyoung, Jea Tahk Seung, Soo Park Keum, Rok Han Kyoo, Hoon Ahn Tae, Hyun Kim Moo, Bae Seung Ki, Sung Chung Wook, Young Yang Ju, Yun Rhim Chong, Cheol Gwon Hyeon, Wook Park Seong, Youp Koh Young, Jae Joo Seung, Joong Kim Soo, Kyu Jin Dong, Man Cho Jin, Gwan Cho Jeong

Research output: Contribution to journalArticlepeer-review

42 Citations (Scopus)


Background: Percutaneous coronary intervention (PCI) with drug-eluting stents (DES) may be useful in patients with acute myocardial infarction (AMI), but safety issues still need to be solved. This study was undertaken to investigate the incidence of major adverse cardiac events (MACE) and stent thrombosis in DES-implanted AMI patients in real-life clinical practice. Methods and Results: On-line registry of AMI cases at the web site has been performed in 41 primary PCI centers in Korea and between November 2005 and September 2006, 1,541 surviving patients who had been implanted with either Cypher® or Taxus® stents were enrolled for analysis during a 6-month clinical follow-up. There were 2 groups: group I [834 patients, 61.9±11.9 years: sirolimus-eluting stent (Cypher®)], group H [707 patients, 62.9±12.0 years: paclitaxel-eluting stent (Taxus®)]. At both 1 and 6 months the incidence of MACE was not significantly different between the 2 groups. There were 17 cases of stent thrombosis, but the incidence of stent thrombosis was not significantly different between the2 groups (group I:II=9 (1.1%): 8 (1.1%), p=1.000). The stent type, length, number, lesion complexity and diabetes were not significant for the incidence of MACE or stent thrombosis after adjustment. Conclusion: MACE and stent thrombosis rates did not differ between 2 types of DES identified in Korea Acute Myocardial Infarction Registry (KAMIR). DES can be used in patients with AMI with a relatively low 6-month MACE rate.

Original languageEnglish
Pages (from-to)392-398
Number of pages7
JournalCirculation Journal
Issue number3
Publication statusPublished - 2008


  • Angioplasty
  • Korea
  • Major adverse cardiac events (MACE)
  • Myocardial infarction
  • Stents

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Clinical safety of drug-eluting stents in the Korea acute myocardial infarction registry'. Together they form a unique fingerprint.

Cite this